Matches in Wikidata for { <http://www.wikidata.org/entity/Q62042058> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- Q62042058 description "clinical trial" @default.
- Q62042058 description "ensayu clínicu" @default.
- Q62042058 description "klinisch onderzoek" @default.
- Q62042058 description "клінічне випробування" @default.
- Q62042058 description "临床试验" @default.
- Q62042058 name "Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma" @default.
- Q62042058 type Item @default.
- Q62042058 label "Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma" @default.
- Q62042058 prefLabel "Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma" @default.
- Q62042058 P1050 Q62042058-E38E866E-5F3A-4B7E-8048-9201398F82DB @default.
- Q62042058 P1132 Q62042058-DC47ECF4-E3BD-44E4-987B-BAD7C6C7ECDA @default.
- Q62042058 P1476 Q62042058-1357C0FA-B3D5-455D-BC06-5626DF4FB8E0 @default.
- Q62042058 P17 Q62042058-3AA2FFC2-10B9-4989-B714-D3DF6AF924FA @default.
- Q62042058 P17 Q62042058-3FAC3717-2D17-4239-9AE5-260BA0025981 @default.
- Q62042058 P17 Q62042058-40571CEB-C157-43D6-B6B6-1DA7F1C7D59C @default.
- Q62042058 P17 Q62042058-4973C6AE-DDBB-42CC-A540-A772F9E06565 @default.
- Q62042058 P17 Q62042058-4C3F952E-6513-4B50-BB57-DE02B8696341 @default.
- Q62042058 P17 Q62042058-62FF9F00-ABA6-4BC7-887D-A6F6DDEFD3FA @default.
- Q62042058 P17 Q62042058-66B50B44-37DA-4F9A-993A-DADD68E218FE @default.
- Q62042058 P17 Q62042058-8275A0FB-526E-4FBA-A880-760B9009B829 @default.
- Q62042058 P17 Q62042058-B1BB1304-417A-471F-9FEB-7AEC1292968B @default.
- Q62042058 P17 Q62042058-BC6D3579-2086-4877-8A81-0A6A42548F92 @default.
- Q62042058 P17 Q62042058-C8533BC5-6C35-4B04-B2EA-22ECC7132D38 @default.
- Q62042058 P17 Q62042058-D92C08C8-B10C-4844-BAB8-48796F379DBB @default.
- Q62042058 P1813 Q62042058-EC954E0F-0491-475C-8E02-F325016672FD @default.
- Q62042058 P2899 Q62042058-7A5840E4-EB40-4F0E-8A89-D3B229DF32ED @default.
- Q62042058 P3098 Q62042058-6EEA2E93-BEF9-45F7-85AA-82C7D41DCC23 @default.
- Q62042058 P31 Q62042058-C8E08F53-9B59-4DCA-8D3F-5F711A97155A @default.
- Q62042058 P4135 Q62042058-737BB208-7B4F-4071-A3FA-F0B419D31964 @default.
- Q62042058 P4844 Q62042058-0262F5C9-F073-4E6A-AC71-A5D00646291A @default.
- Q62042058 P4844 Q62042058-3D507BD4-E4A8-4EF2-95EA-EB71D8F68E3F @default.
- Q62042058 P4844 Q62042058-59BE60F1-8F6B-433B-8AA7-FCC170B8837C @default.
- Q62042058 P4844 Q62042058-74A8A7F6-54E9-4EA8-9C1D-0863B2097C40 @default.
- Q62042058 P4844 Q62042058-87EDEEA4-439A-44F8-AE8C-BE9CAAE24660 @default.
- Q62042058 P4844 Q62042058-C952B5F5-A7AC-4209-AAF8-FC3EE5079A2F @default.
- Q62042058 P580 Q62042058-0268A330-B074-4CD4-84D8-FC2447BF2052 @default.
- Q62042058 P582 Q62042058-01E0EEB1-70A1-4F6C-9ACA-68D62E5C753F @default.
- Q62042058 P6099 Q62042058-AAB52F73-F5E2-4961-8691-A3C1F666C5AA @default.
- Q62042058 P6153 Q62042058-04362C8F-A5B6-4A17-A998-197ECD218042 @default.
- Q62042058 P6153 Q62042058-18B02A54-E06A-49BC-805E-C3A0627720BD @default.
- Q62042058 P6153 Q62042058-60D8E8C7-C960-48C1-937E-CB233DC22243 @default.
- Q62042058 P6153 Q62042058-D9D24F29-34B0-49C6-AF8E-3C8C15DC75C6 @default.
- Q62042058 P6153 Q62042058-DBEBC3BD-7193-49DE-A25E-339858155D4C @default.
- Q62042058 P8005 Q62042058-6A411473-CDEB-4BB0-9EF0-A3B8D5CF2477 @default.
- Q62042058 P8363 Q62042058-9D1277FA-87F6-4A10-B5D7-1998A4F935AC @default.
- Q62042058 P859 Q62042058-C5EE2052-A1E3-4EE9-B092-3A17F21C5807 @default.
- Q62042058 P1050 Q467635 @default.
- Q62042058 P1132 "+690" @default.
- Q62042058 P1476 "A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy" @default.
- Q62042058 P17 Q142 @default.
- Q62042058 P17 Q20 @default.
- Q62042058 P17 Q29 @default.
- Q62042058 P17 Q31 @default.
- Q62042058 P17 Q35 @default.
- Q62042058 P17 Q36 @default.
- Q62042058 P17 Q38 @default.
- Q62042058 P17 Q39 @default.
- Q62042058 P17 Q408 @default.
- Q62042058 P17 Q41 @default.
- Q62042058 P17 Q43 @default.
- Q62042058 P17 Q55 @default.
- Q62042058 P1813 "Perseus" @default.
- Q62042058 P2899 "+18" @default.
- Q62042058 P3098 "NCT03710603" @default.
- Q62042058 P31 Q30612 @default.
- Q62042058 P4135 "+70" @default.
- Q62042058 P4844 Q15889608 @default.
- Q62042058 P4844 Q203174 @default.
- Q62042058 P4844 Q408524 @default.
- Q62042058 P4844 Q419319 @default.
- Q62042058 P4844 Q425681 @default.
- Q62042058 P4844 Q5222113 @default.
- Q62042058 P580 "2018-12-14T00:00:00Z" @default.
- Q62042058 P582 "2029-05-01T00:00:00Z" @default.
- Q62042058 P6099 Q42824827 @default.
- Q62042058 P6153 Q11989351 @default.
- Q62042058 P6153 Q1728153 @default.
- Q62042058 P6153 Q486156 @default.
- Q62042058 P6153 Q633529 @default.
- Q62042058 P6153 Q81949 @default.
- Q62042058 P8005 Q76649708 @default.
- Q62042058 P8363 Q78089383 @default.
- Q62042058 P859 Q57166498 @default.